Structure Therapeutics reports more Phase 2 data for oral GLP-1
结构治疗公司公布更多口服GLP-1的2期数据

Structure Therapeutics has its much-anticipated oral GLP-1 data, and the results look to give the next-generation contender a chance against market incumbents Eli Lilly and Novo Nordisk.
结构治疗公司公布了备受期待的口服GLP-1数据，结果显示这款下一代竞争者有望向市场现有巨头礼来和诺和诺德发起挑战。